Genocea Biosciences has dosed the first patients in its Phase I/IIa clinical trial evaluating the safety, immunogenicity, and clinical efficacy of GEN-009 for the treatment of cancer.

Part A of the three-part trial is designed to investigate the safety and immunogenicity of GEN-009 as monotherapy in cancer patients who have no evidence of disease but are at high risk of relapse.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The first part of the trial saw Genocea enrol nine patients who earlier received treatments for melanoma, non-small cell lung cancer, head and neck cancer, or urothelial carcinoma.

Once immunogenicity data is achieved from these patients, Genocea plans to commence Parts B and C of the Phase I/IIa trial.

“With Part A of the trial now fully enrolled, we are in a better position to predict when we will have the first immunogenicity data from these patients.”

Part B is expected to see GEN-009 evaluated in combination with checkpoint inhibitors in patients with advanced or metastatic solid tumours.

Part C will involve patients whose disease has progressed in spite of checkpoint inhibitor therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Genocea Biosciences chief medical officer Dr Tom Davissaid: “Importantly, our GEN-009 vaccines use our ATLAS platform for neoantigen identification.

“Unlike machine-based approaches that predict neoantigens and only evaluate the patient’s tumour, ATLAS also uses each patient’s own immune cells not only to identify true neoantigens that already trigger anti-tumour cytokine responses, but also to eliminate inhibitory antigens that are frequently selected for vaccine inclusion by such in silico approaches.”

Dr Davis further added: “With Part A of the trial now fully enrolled, we are in a better position to predict when we will have the first immunogenicity data from these patients.

“As a result, we are updating our guidance today and look forward to reporting top-line results from this part of the study late in the second quarter of this year or early in the third quarter.”